| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
proteases[2], renin[2], angiotensin-converting enzyme[2]
Proteases; Renin; Angiotensin-converting enzyme (ACE) |
|---|---|
| ln Vitro |
19.4% (40 μg/mL) of renin activity is inhibited by licumin A.
Lyciumin A demonstrates inhibitory activity against proteases, renin, and ACE. In particular, it inhibits renin activity by 19.4% at a concentration of 40 microg/mL. It may also have neuroprotective and antioxidant properties. |
| ln Vivo |
Currently, no specific in vivo data is available for this compound. General in vivo information for similar ACE inhibitors may include their ability to lower blood pressure in animal models of hypertension and protect against angiotensin II-induced organ damage.
|
| Enzyme Assay |
A typical enzyme inhibition assay protocol for renin involves incubating the compound with renin and its substrate, angiotensinogen, in a buffer. The amount of angiotensin I generated is measured by radioimmunoassay or ELISA. For ACE, a fluorometric assay using a substrate like Abz-FRK(Dnp)-P is commonly used.
|
| Cell Assay |
General in vitro cellular protocols for cyclic peptides may involve culturing human umbilical vein endothelial cells (HUVECs) or smooth muscle cells. Cells are pre-incubated with the compound and then stimulated with angiotensin II. Markers of oxidative stress (e.g., ROS) and inflammation (e.g., ICAM-1) are measured.
|
| Animal Protocol |
General in vivo procedures for hypertension research involve using spontaneously hypertensive rats (SHRs). The compound is administered via oral gavage or intraperitoneal injection. Blood pressure is measured using the tail-cuff method. Blood and tissue samples are collected for ex vivo analysis of renin and ACE activity.
|
| ADME/Pharmacokinetics |
General PK properties for cyclic peptides often include low oral bioavailability due to poor intestinal permeability and susceptibility to proteolytic degradation. They typically have a short half-life when administered intravenously and are cleared primarily by renal excretion.
|
| Toxicity/Toxicokinetics |
General toxicity data for cyclic peptides isolated from natural sources often suggests low acute toxicity, but detailed safety profiles are typically lacking. High doses may cause gastrointestinal disturbances. Cytotoxicity is generally assessed in vitro using cell lines to determine a therapeutic window.
|
| References | |
| Additional Infomation |
Lyciumin A is a cyclic peptide. It has been reported that Lyciumin A is found in wolfberry (Lycium chinense), and relevant data is available for reference.
Lyciumin A is a cyclic octapeptide derived from plants of the Lycium genus. Its mechanism of action is thought to be through direct inhibition of key enzymes in the renin-angiotensin system. It is a tool for studying hypertension and a lead compound for drug development. It is not an approved drug. |
| Molecular Formula |
C42H51N9O12
|
|---|---|
| Molecular Weight |
873.91
|
| Exact Mass |
873.366
|
| CAS # |
125708-06-7
|
| PubChem CID |
14430290
|
| Appearance |
White to off-white solid powder
|
| LogP |
0.182
|
| Hydrogen Bond Donor Count |
10
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
63
|
| Complexity |
1760
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C)C1C(=O)NCC(=O)NC(C(=O)NC(CC2=CN(C(C(=O)N1)NC(=O)C(CC3=CC=C(C=C3)O)NC(=O)C4CCCN4C(=O)C5CCC(=O)N5)C6=CC=CC=C26)C(=O)O)CO
|
| InChi Key |
IPOLXDNCMOVXCP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C42H51N9O12/c1-21(2)34-39(59)43-18-33(55)45-29(20-52)37(57)47-28(42(62)63)17-23-19-51(30-7-4-3-6-25(23)30)35(40(60)48-34)49-36(56)27(16-22-9-11-24(53)12-10-22)46-38(58)31-8-5-15-50(31)41(61)26-13-14-32(54)44-26/h3-4,6-7,9-12,19,21,26-29,31,34-35,52-53H,5,8,13-18,20H2,1-2H3,(H,43,59)(H,44,54)(H,45,55)(H,46,58)(H,47,57)(H,48,60)(H,49,56)(H,62,63)
|
| Chemical Name |
11-(hydroxymethyl)-2-[[3-(4-hydroxyphenyl)-2-[[1-(5-oxopyrrolidine-2-carbonyl)pyrrolidine-2-carbonyl]amino]propanoyl]amino]-3,6,9,12-tetraoxo-5-propan-2-yl-1,4,7,10,13-pentazatricyclo[14.6.1.017,22]tricosa-16(23),17,19,21-tetraene-14-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1443 mL | 5.7214 mL | 11.4428 mL | |
| 5 mM | 0.2289 mL | 1.1443 mL | 2.2886 mL | |
| 10 mM | 0.1144 mL | 0.5721 mL | 1.1443 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
